PTP4A3 and leukemia: Our results could also be important in explaining previous observations that doxorubicin was more effective in PRL3-silenced leukemia cells [11], and the results of a drug screen showing that a chemical inhibitor of PRL3 strengthened the antitumor effect of cisplatin [10].